Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Apr
26
Today In Oncology
Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564
Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting
Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care
Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside